--- title: "U.S. stock market midday update: BiomX up 22.54% with increased trading volume, market sentiment is high but volatility should be monitored" type: "News" locale: "en" url: "https://longbridge.com/en/news/287087469.md" description: "BiomX rose 22.54%; Immunovant rose 34.16%, with a trading volume of USD 318 million; Amgen fell 0.35%, with a trading volume of USD 300 million; HCW Biologics rose 178.30%, with a trading volume of USD 216 million; AbbVie fell 0.55%, with a market value of USD 375.5 billion" datetime: "2026-05-20T14:58:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287087469.md) - [en](https://longbridge.com/en/news/287087469.md) - [zh-HK](https://longbridge.com/zh-HK/news/287087469.md) --- # U.S. stock market midday update: BiomX up 22.54% with increased trading volume, market sentiment is high but volatility should be monitored **U.S. Stock Market Midday Update** BiomX, up 22.54%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Immunovant up 34.16%. Based on recent key news: 1. On May 20, Immunovant announced encouraging results for its new rheumatoid arthritis treatment, with the stock price soaring to its highest level in the past 18 months. Investors reacted positively to this breakthrough, driving the stock price up. 2. On May 20, Immunovant announced the cessation of batoclimab's development, shifting focus to the research and development of IMVT-1402. The company expects IMVT-1402 to have significant market opportunities in multiple autoimmune diseases. 3. On May 20, Immunovant reported a fourth-quarter loss per share of $0.73, with operating expenses of $159.554 million. Despite poor financial performance, strong cash reserves support its ongoing clinical and commercial execution. The biotechnology sector has performed strongly recently, with noticeable capital inflow. Amgen down 0.35%, with increased trading volume. Based on recent key news: 1. On May 19, Amgen announced the retirement of Chief Financial Officer Peter Griffith, with Thomas Dittrich to succeed him. This news may raise market concerns about the company's financial management, leading to stock price volatility. 2. On May 20, Amgen performed steadily in the biotechnology sector, with a slight stock price increase of 1.96%. Market recognition of its R&D investments and strategic partnerships drove the stock price up. 3. On May 20, global economic conditions may amplify certain risks, affecting the company's business performance and shareholder return capabilities. This macroeconomic factor may put pressure on the stock price. Innovation in the biotechnology sector continues, and market risks need attention. HCW Biologics up 178.30%. Based on recent key news: 1. On May 19, HCW Biologics' RSI reached 84.20, indicating an overbought state, with the stock price facing a risk of correction. Technical indicators show increased short-term momentum risk, with the stock price dropping 17.16% at $1.12. Source: Benzinga 2. On May 18, the RSI was 82.75, indicating a risk of correction and profit-taking after a rapid stock price increase. The stock price dropped 19.09% at $0.98. Source: Benzinga 3. Recent technical analysis shows that the 20-day moving average is below the 50-day moving average, and the 50-day moving average is below the 200-day moving average, indicating a long-term bearish trend. Source: Benzinga Market momentum risk is increasing, and technical indicators need attention **Stocks Ranked Among the Top by Market Capitalization in the Industry** AbbVie fell 0.55%. Based on recent key news: 1. On May 19, Belgian biopharmaceutical company UCB announced Phase III study data for its IL-17A/IL-17F inhibitor Bimzelx, showing it outperformed AbbVie's blockbuster IL-23 inhibitor Skyrizi in treating psoriatic arthritis. This result negatively impacted AbbVie's market competitiveness, leading to a decline in stock price. 2. On May 20, Rongchang Biologics announced it would license its PD-1/VEGF dual antibody RC148 to AbbVie for an upfront payment of $650 million. Although this collaboration brings short-term liquidity to AbbVie, the market remains skeptical about its long-term profitability, affecting stock performance. 3. On May 17, MarketBeat reported that despite AbbVie currently having a moderate buy rating among analysts, top analysts believe there are five stocks more worthy of investment than AbbVie. This news weakened market confidence in AbbVie, leading to a decline in stock price. Competition in the pharmaceutical industry is intensifying, with innovative pharmaceutical companies performing strongly ### Related Stocks - [PHGE.US](https://longbridge.com/en/quote/PHGE.US.md) - [IMVT.US](https://longbridge.com/en/quote/IMVT.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [HCWB.US](https://longbridge.com/en/quote/HCWB.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) ## Related News & Research - [BiomX Delays Quarterly Report Amid Strategic Shift](https://longbridge.com/en/news/286624580.md) - [Should you invest $1,000 in AGNC Investment right now?](https://longbridge.com/en/news/286802595.md) - [TGT Stock Alert: What to Know as Target Taps Former Walmart Exec](https://longbridge.com/en/news/286957668.md) - [This High-Yield REIT Just Hiked Its Dividend By 7.1%. Its Shares Look Compelling Here.](https://longbridge.com/en/news/286976827.md) - [New SOUR PATCH KIDS CHEWS are Here to Challenge the Candy Status Quo | MDLZ Stock News](https://longbridge.com/en/news/286929752.md)